AP2015008306A0 - Methods of treating alzheimer's disease and pharmaceutical compositions thereof - Google Patents
Methods of treating alzheimer's disease and pharmaceutical compositions thereofInfo
- Publication number
- AP2015008306A0 AP2015008306A0 AP2015008306A AP2015008306A AP2015008306A0 AP 2015008306 A0 AP2015008306 A0 AP 2015008306A0 AP 2015008306 A AP2015008306 A AP 2015008306A AP 2015008306 A AP2015008306 A AP 2015008306A AP 2015008306 A0 AP2015008306 A0 AP 2015008306A0
- Authority
- AP
- ARIPO
- Prior art keywords
- disease
- methods
- pharmaceutical compositions
- treating alzheimer
- alzheimer
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698664P | 2012-09-09 | 2012-09-09 | |
| US201361782084P | 2013-03-14 | 2013-03-14 | |
| PCT/EP2013/068516 WO2014037532A1 (en) | 2012-09-09 | 2013-09-06 | Methods of treating alzheimer's disease and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2015008306A0 true AP2015008306A0 (en) | 2015-03-31 |
Family
ID=49118521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2015008306A AP2015008306A0 (en) | 2012-09-09 | 2013-09-06 | Methods of treating alzheimer's disease and pharmaceutical compositions thereof |
Country Status (33)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1558582T3 (da) | 2003-07-22 | 2006-05-08 | Arena Pharm Inc | Diaryl og arylheteroarylureaderivater som modulatorer af aktiviteten af 5-HT2A-serotoninreceptoren anvendelige til profylakse eller behandling af forstyrrelser relateret dertil |
| WO2009074607A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| PE20151727A1 (es) | 2013-03-14 | 2015-12-17 | Boehringer Ingelheim Int | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c |
| JP6467404B2 (ja) | 2013-03-14 | 2019-02-13 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐ２ｘ７モジュレーター |
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| EP3112366B1 (en) | 2013-03-14 | 2018-02-28 | Janssen Pharmaceutica NV | P2x7 modulators |
| JO3639B1 (ar) | 2014-07-04 | 2020-08-27 | H Lundbeck As | صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد |
| MX367316B (es) | 2014-09-12 | 2019-08-15 | Boehringer Ingelheim Int | Inhibidores espirociclicos de catepsina c. |
| US10150766B2 (en) | 2014-09-12 | 2018-12-11 | Janssen Pharmaceutica Nv | P2X7 modulators |
| EA201790600A1 (ru) | 2014-09-12 | 2017-07-31 | Янссен Фармацевтика Нв | Модулирующие p2x7 n-ацил-триазолопиразины |
| CN105175307A (zh) * | 2014-11-18 | 2015-12-23 | 苏州晶云药物科技有限公司 | Lu AE58054的盐酸盐晶型A及其制备方法和用途 |
| US20160324852A1 (en) * | 2015-05-07 | 2016-11-10 | Axovant Sciences Ltd. | Compositions and methods of treating a neurodegenerative disease |
| EP3307260A4 (en) | 2015-06-12 | 2019-02-13 | Axovant Sciences GmbH | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES FOR PROPHYLAXIS AND TREATMENT OF SLEEP BEHAVIORAL DISORDERS IN THE REM PHASE |
| MX391031B (es) | 2015-07-15 | 2025-03-21 | Axovant Sciences Gmbh | Derivados de diaril y arilheteroaril urea como moduladores del receptor de serotonina 5-ht2a útiles para la profilaxis y el tratamiento de alucinaciones asociadas con una enfermedad neurodegenerativa. |
| AU2017256623B2 (en) * | 2016-04-26 | 2022-07-21 | H. Lundbeck A/S | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in Parkinson's disease patients |
| US10864191B2 (en) * | 2016-05-11 | 2020-12-15 | H. Lundbeck A/S | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity |
| PT3484467T (pt) | 2016-05-18 | 2020-06-16 | Suven Life Sciences Ltd | Combinação de antagonistas puros do recetor 5-ht6 com inibidores de acetilcolinesterase |
| CN106309436A (zh) * | 2016-07-25 | 2017-01-11 | 宁波大学 | 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途 |
| CN107118146B (zh) * | 2017-04-13 | 2019-09-03 | 宁波大学 | 一种6-溴色胺衍生物及其制备方法和用途 |
| LT3630098T (lt) | 2017-05-24 | 2021-05-25 | H. Lundbeck A/S | 5-ht6 receptoriaus antagonisto ir acetilcholinesterazės inhibitoriaus derinys, skirtas naudoti gydant alzheimerio ligą pacientų pogrupyje, turiančiame apoe4 aliejus |
| TWI863931B (zh) | 2018-09-28 | 2024-12-01 | 比利時商健生藥品公司 | 單醯基丙三醇脂酶調節劑 |
| AU2019349962A1 (en) | 2018-09-28 | 2021-03-18 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| ES3037365T3 (en) | 2019-09-30 | 2025-10-01 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
| NL2024431B1 (en) | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
| EP4126860A1 (en) | 2020-03-26 | 2023-02-08 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
| EP3960174B1 (en) | 2020-08-28 | 2024-10-30 | Westfälische Wilhelms-Universität Münster | Parasympathetic active phenyl-glycosid-substituted hydroxy-methyl-piperidine and -pyrrolidine alkaloids for medicinal use |
| CN121013715A (zh) * | 2024-03-22 | 2025-11-25 | 艾瑞克·奎因 | 镁和利多卡因组合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3597149A (en) | 1969-04-29 | 1971-08-03 | Showa Denko Kk | Inhibition of gas-fume fading of dyed cellulose acetate material |
| FR2181559A1 (en) | 1972-04-28 | 1973-12-07 | Aec Chimie Organique Bio | N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity |
| JPS5764632A (en) | 1980-10-09 | 1982-04-19 | Mitsui Toatsu Chem Inc | Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide |
| DE3632329A1 (de) | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| US5202336A (en) | 1986-09-24 | 1993-04-13 | Bayer Aktiengesellschaft | Antiflammatory quinolin methoxy phenylsulphonamides |
| SE9103745D0 (sv) | 1991-12-18 | 1991-12-18 | Wikstroem Haakan | Aryl-triflates and related compounds |
| WO1995006638A1 (en) | 1993-09-01 | 1995-03-09 | Allelix Biopharmaceuticals Inc. | Tryptamine analogs with 5-ht1d selectivity |
| US5504101A (en) | 1994-05-06 | 1996-04-02 | Allelix Biopharmaceuticals, Inc. | 5-HT-1D receptor ligands |
| PT1032559E (pt) | 1997-09-29 | 2007-02-28 | Aventis Pharma Inc | Derivados de aminoalquilfenol para tratamento de depressão e disfunção da memória |
| GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| ATE319683T1 (de) | 1998-12-11 | 2006-03-15 | Univ Virginia Commonwealth | Selektive 5-ht 6-rezeptor-liganden |
| OA11820A (en) | 1999-01-13 | 2005-08-17 | Warner Lambert Co | Functionalized heterocycles as chemokine receptor modulators. |
| US6750348B1 (en) | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| US7157488B2 (en) * | 2001-03-29 | 2007-01-02 | Eli Lilly And Company | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor |
| RU2252936C2 (ru) * | 2002-12-05 | 2005-05-27 | Институт физиологически активных веществ РАН | S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты) |
| PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| CN101500611A (zh) | 2006-06-23 | 2009-08-05 | 埃斯蒂维实验室股份有限公司 | 胆碱脂酶抑制剂与具有5-ht6受体亲和力的化合物的组合 |
| AR061637A1 (es) | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| MX2012000939A (es) * | 2009-07-23 | 2012-06-08 | Shire Llc | Profarmacos de peptidos y aminoacidos de galantamina y usos de los mismos. |
| TW201139370A (en) | 2009-12-23 | 2011-11-16 | Lundbeck & Co As H | Processes for the manufacture of a pharmaceutically active agent |
| JO3459B1 (ar) * | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
-
2013
- 2013-08-21 JO JOP/2013/0248A patent/JO3459B1/ar active
- 2013-09-06 SG SG11201501774QA patent/SG11201501774QA/en unknown
- 2013-09-06 EA EA201590353A patent/EA030448B1/ru not_active IP Right Cessation
- 2013-09-06 ES ES13759195T patent/ES2703630T3/es active Active
- 2013-09-06 WO PCT/EP2013/068516 patent/WO2014037532A1/en not_active Ceased
- 2013-09-06 DK DK13759195.4T patent/DK2892563T3/en active
- 2013-09-06 MX MX2015002879A patent/MX368305B/es active IP Right Grant
- 2013-09-06 NZ NZ630589A patent/NZ630589A/en unknown
- 2013-09-06 RS RS20181571A patent/RS58104B1/sr unknown
- 2013-09-06 CN CN201380046768.6A patent/CN104619344A/zh active Pending
- 2013-09-06 AP AP2015008306A patent/AP2015008306A0/xx unknown
- 2013-09-06 PT PT13759195T patent/PT2892563T/pt unknown
- 2013-09-06 JP JP2015530420A patent/JP6693744B2/ja active Active
- 2013-09-06 CA CA2883751A patent/CA2883751C/en active Active
- 2013-09-06 BR BR112015005117-0A patent/BR112015005117B1/pt active IP Right Grant
- 2013-09-06 EP EP13759195.4A patent/EP2892563B1/en active Active
- 2013-09-06 SM SM20180678T patent/SMT201800678T1/it unknown
- 2013-09-06 SI SI201331303T patent/SI2892563T1/sl unknown
- 2013-09-06 TW TW102132182A patent/TWI632909B/zh active
- 2013-09-06 HR HRP20182069TT patent/HRP20182069T1/hr unknown
- 2013-09-06 LT LTEP13759195.4T patent/LT2892563T/lt unknown
- 2013-09-06 MY MYPI2015000575A patent/MY182539A/en unknown
- 2013-09-06 KR KR1020207034028A patent/KR102342127B1/ko active Active
- 2013-09-06 AU AU2013311573A patent/AU2013311573B2/en active Active
- 2013-09-06 KR KR1020157007345A patent/KR20150065680A/ko not_active Ceased
- 2013-09-06 GE GEAP201313752A patent/GEP201706776B/en unknown
- 2013-09-06 PL PL13759195T patent/PL2892563T3/pl unknown
- 2013-09-06 RU RU2015107877A patent/RU2675786C2/ru active
- 2013-09-09 US US14/021,033 patent/US9375418B2/en active Active
-
2015
- 2015-02-23 IL IL237369A patent/IL237369B/en active IP Right Grant
- 2015-03-02 TN TNP2015000076A patent/TN2015000076A1/fr unknown
- 2015-03-06 NI NI201500031A patent/NI201500031A/es unknown
- 2015-03-06 CL CL2015000578A patent/CL2015000578A1/es unknown
-
2016
- 2016-03-30 US US15/084,712 patent/US9687473B2/en active Active
- 2016-06-28 US US15/194,947 patent/US9789085B2/en active Active
-
2017
- 2017-09-06 US US15/696,880 patent/US10660878B2/en active Active
-
2018
- 2018-12-06 JP JP2018228631A patent/JP2019059760A/ja active Pending
- 2018-12-21 CY CY181101390T patent/CY1121062T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237369A0 (en) | Methods for treating Alzheimer's disease and pharmaceutical compositions thereof | |
| IL266582A (en) | Preparations and methods for the treatment of hemoglobin diseases | |
| EP2707369A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | |
| IL236221A (en) | History of theophyridone and pharmacological preparations containing them for the treatment of diseases | |
| HUE041553T2 (hu) | Lizoszomális tárolási betegségek (LSD) kezelése és génterápia | |
| IL236054B (en) | Compositions and methods for treating Crohn's disease and related conditions and infections | |
| EP2925775A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLISM DISEASES AND DRESSINGS | |
| ZA201406209B (en) | Methods and compositions for treating huntington's disease | |
| HUE053113T2 (hu) | Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra | |
| PL3378862T3 (pl) | Dihydropirymidynoizochinolinony i ich kompozycie farmaceutyczne do leczenia stwardnienia rozsianego | |
| ZA201406145B (en) | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use | |
| ZA201500561B (en) | Compositions and treatment for eye diseases and disorders | |
| SG11201403272YA (en) | Compositions and methods for treating alzheimer's disease | |
| IL233639A0 (en) | Preparations and methods for the treatment of diseases and liver disorders | |
| EP2568811A4 (en) | TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER | |
| GB201310150D0 (en) | Methods and compositions relating to alzheimer's disease | |
| IL234606A0 (en) | Innovative methods and compounds for the treatment of diseases | |
| SG10201704712QA (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| IL237730B (en) | Treatment of mild and moderate Alzheimer's disease | |
| PL2892556T3 (pl) | Kompozycje i sposoby odnoszące się do leczenia chorób | |
| AP2014007905A0 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| GB201101088D0 (en) | L-carnosine and cinnamon extract for the treatment of Alzheimer's Disease | |
| GB201113718D0 (en) | Treatment of Dupuytren's Disease | |
| HK1195902A (en) | Compositions and methods for treating alzheimer's disease |